German Minister's "Alarm" At Spending

18 December 1995

German Health Minister Horst Seehofer says health spending development in the first nine months of 1995 is "dramatic and alarming," with a deficit of 7.5 billion Deutschemarks ($5.17 billion). The western states accounted for 5.8 billion marks of the total and the eastern states for the balance.

Spending per health fund member rose 5.5% in western germany compared with a rise of only 0.6% in basic wage rates, while eastern health spending rose 10.5% compared with a 1% rise in contribution income. The deficit would have risen further in the fourth quarter, he said, and he did not exclude the possibility that the 10 billion marks figure would be reached.

He said the public sector was the deficit's main source, due to changes in contributions of the unemployed and other factors. The second source was the hospital sector; the funds spent 3.5 billion marks more in the reporting period on hospital treatment than would be justified in terms of basic wage rate growth. The minister again called for restraint from doctors in prescribing, and reminded the health service that it had agreed to restrict hospital spending growth to basic wages growth. Since the hospitals had not kept their part of the bargain, policy would now have to be directed to impose budgest to cure what he called "this irrationality."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight